Saikosaponin B2与DACLATASVIR结合使用NS5A耐药性相关的丙型肝炎病毒的抗病毒作用

Wei-Ping Lee, Keng-Li Lan, Shi-Xian Liao, Yi-Hsiang Huang, Ming-Chih Hou, Keng-Hsin Lan

Wei-Ping Lee

BACKGROUND: Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis, cirrhosis, and hepatocellular carcinoma.直接作用抗病毒药的发展的快速进步大大提高了治愈率的恢复率≥95％T年。 However, the high cost of treatment is not affordable to patients in some countries, necessitating the development of less expensive treatment.

METHODS: We adopted a cell culture-derived HCV system to screen a library of the pure compounds extracted from herbs deposited in the chemical bank of the National Research Institute of Chinese Medicine,台湾。

结果： 我们发现saikosaponin b2抑制了病毒进入，复制和翻译。 Saikosaponin B2是一种植物糖苷，也是Xiao-chai-hu-tang的组成部分，这是一种从bupleurum falcatum的根中提取的中胃药。它还抑制了HCV的抗Daclatasvir突变菌株，尤其是与daclatasvir结合。

结论： 我们的结果可能有助于对患者的新结合治疗的开发。ITH HCV对当前可用的药物不耐受或难治性，包括pe节制干扰素和直接作用抗病毒药。